article thumbnail

Cannabinoids for Scleroderma

Project CBD

Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2.

article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Ehave, Inc. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Cannabis Law Report

Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. ” About Ehave, Inc. Ehave, Inc. Email: ir@ehave.com.

article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. In Canada, mental health issues affect more than 6.7

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. Visit [link].

article thumbnail

Justice Department Urged To Take “Immediate Action” On Marijuana Grow Applications

NORML

Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” The agency said that the policy change was necessary because the existing system provided “no clear legal pathway for commercial enterprises to produce marijuana for product development.”

DEA 197